Top 5 Stocks Under $5 That Could Triple

3. ProQR Therapeutics N.V. (NASDAQ:PRQR)

ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple.

As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA editing platform and future clinical catalysts.

ProQR Therapeutics N.V. (NASDAQ:PRQR) reported full-year 2025 results on March 12, 2026. The company noted the ongoing development of AX-0810 in a Phase 1 trial, with target engagement data anticipated in 1H 2026.

CEO Daniel de Boer described this as a key milestone for ProQR Therapeutics N.V. (NASDAQ:PRQR), which follows pipeline expansion with AX-2402 in Rett syndrome and AX-2911 in MASH. Furthermore, the business received $4.50 million in milestone payments under its agreement with Eli Lilly, providing runway into mid-2027. Early AX-0810 studies showed encouraging pharmacokinetics and safety, with plans to include patients with PSC.

During the quarter, cash decreased to $105.96 million, R&D increased to $51.26 million, and net loss widened to $48.62 million, or $0.46 per share, while ProQR Therapeutics N.V. (NASDAQ:PRQR)’s continued pipeline development remains a central focus for investors.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a clinical-stage biotechnology company focused on developing RNA therapeutics for severe rare genetic diseases, including inherited retinal impairments, using its patented platform to address unmet medical needs.